Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 2/3 trial studying pimurutamab HLX07 in combination with Hansizhuang and chemotherapy in the Chinese Mainland, according to a Tuesday filing with the Hong Kong bourse.
The drug in this combination is being compared to a placebo in combination with Hansizhuang or pembrolizumab and chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer.
Jubilant Ingrevia (NSE:JUBLINGREA, BOM:543271) recommended a final dividend of 2.50 rupees per share for the financial year ended March 31, according to an Indian bourse filing on Tuesday.If approved, the dividend will be paid to shareholders of record on July 24, the filing said.
Guangzhou Ruili Komi Automotive Electronics (SHE:001285) will contribute 20 million yuan to a 1.16-billion-yuan fund focused on new energy vehicles and advanced manufacturing.The investment gives the company a 1.7% stake in the Ningbo Yongyuan Junsheng fund, according to a Tuesday filing with the Shenzhen bourse.
Responsive Industries (NSE:RESPONIND, BOM:505509) has appointed Aayush Agarwal as non-executive non-independent director and chairperson of the company, subject to shareholder approval, according to an Indian bourse filing on Tuesday.